论文部分内容阅读
目的:观察甲地孕酮对晚期肿瘤患者血清IL-6水平及放化疗耐受性的影响。方法:非小细胞肺癌36例,小细胞肺癌10例,鼻咽癌20例,随机分为治疗组(放化疗加甲地孕酮160mg/d)和对照组(单纯放化疗)各33例。分别观察治疗期间血清IL-6水平及放化疗所致消化道反应,血液毒性,体重,食欲,生活质量状态等的变化。结果:治疗组的患者血清的IL-6水平明显降低(P<0.001),消化道反应和血液毒性发生率低于对照组(P<0.05),生活质量改善优于对照组(P<0.01),未见甲地孕酮所致的严重毒副作用。结论:甲地孕酮通过下调血清IL-6水平提高晚期肿瘤患者对放化疗耐受性。
Objective: To observe the effect of megestrol on serum IL-6 in patients with advanced cancer and its radiotherapy and chemotherapy tolerance. Methods: Thirty-six cases of non-small cell lung cancer, 10 cases of small cell lung cancer and 20 cases of nasopharyngeal carcinoma were randomly divided into treatment group (radiotherapy and chemotherapy plus megestrol 160 mg / d) and control group (radiotherapy alone). The change of serum IL-6 level during the treatment and the gastrointestinal reaction, hematological toxicity, body weight, appetite and quality of life condition induced by radiotherapy and chemotherapy were observed. Results: Serum levels of IL-6 in treatment group were significantly lower than those in control group (P <0.001), and the incidence of gastrointestinal reaction and hematotoxicity was lower than that in control group (P <0.05) , No serious side effects caused by megestrol. CONCLUSION: Megestrol can enhance the radiotherapy and chemotherapy tolerance of advanced cancer patients by down-regulating serum IL-6 level.